Urinary PSA and Serum PSA for Aggressive Prostate Cancer Detection
Cancers · 02.02.2023 · 15 (3) · 960
DOI: 10.3390/cancers15030960 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancers, online erschienen am 02.02.2023. Verfasst von Naseruddin Höti und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, Patrick C Walsh Grant, National Institutes of Health.
Abstract (Originalsprache)
Serum PSA, together with digital rectal examination and imaging of the prostate gland, have remained the gold standard in urological practices for the management of and intervention for prostate cancer. Based on these adopted practices, the limitations of serum PSA in identifying aggressive prostate cancer has led us to evaluate whether urinary PSA levels might have any clinical utility in prostate cancer diagnosis. Utilizing the Access Hybritech PSA assay, we evaluated a total of n = 437 urine specimens from post-DRE prostate cancer patients. In our initial cohort, PSA tests from a total of one hundred and forty-six (n = 146) urine specimens were obtained from patients with aggressive (Gleason Score ≥ 8, n = 76) and non-aggressive (Gleason Score = 6, n = 70) prostate cancer. A second cohort, with a larger set of n = 291 urine samples from patients with aggressive (GS ≥ 7, n = 168) and non-aggressive (GS = 6, n = 123) prostate cancer, was also utilized in our study. Our data demonstrated that patients with aggressive disease had lower levels of urinary PSA compared to the non-aggressive patients, while the serum PSA levels were higher in patients with aggressive prostate disease. The discordance between serum and urine PSA levels was further validated by immuno-histochemistry (IHC) assay in biopsied tumors and in metastatic lesions (n = 62). Our data demonstrated that aggressive prostate cancer was negatively correlated with the PSA in prostate cancer tissues, and, unlike serum PSA, urinary PSA might serve a better surrogate for capitulating tissue milieus to detect aggressive prostate cancer. We further explored the utility of urine PSA as a cancer biomarker, either alone and in combination with serum PSA, and their ratio (serum to urine PSA) to predict disease status. Comparing the AUCs for the urine and serum PSA alone, we found that urinary PSA had a higher predictive power (AUC= 0.732) in detecting aggressive disease. Furthermore, combining the ratios between serum to urine PSA with urine and serum assay enhanced the performance (AUC = 0.811) in predicting aggressive prostate disease. These studies support the role of urinary PSA in combination with serum for detecting aggressive prostate cancer.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
- Department of Pathology, University of Maryland Medical Center, Baltimore, MD 21201, USA.
- Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA.
- Department of Urology, The Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
ORCID-Profile: Lori J Sokoll, Hui Zhang
Förderung
- NCI NIH HHS
- Patrick C Walsh Grant
- National Institutes of Health
Zitieren
APA
Höti, N., Lih, T. S., Dong, M., Zhang, Z., Mangold, L., Partin, A. W., Sokoll, L. J., Kay Li, Q., & Zhang, H. (2023). Urinary PSA and Serum PSA for Aggressive Prostate Cancer Detection. Cancers, 15(3), 960. https://doi.org/10.3390/cancers15030960
Vancouver
Höti N, Lih TS, Dong M, Zhang Z, Mangold L, Partin AW, et al. Urinary PSA and Serum PSA for Aggressive Prostate Cancer Detection. Cancers. 2023;15(3):960. doi:10.3390/cancers15030960
BibTeX
@article{Hti2023,
author = {Höti, Naseruddin and Lih, Tung-Shing and Dong, Mingming and Zhang, Zhen and Mangold, Leslie and Partin, Alan W and Sokoll, Lori J and Kay Li, Qing and Zhang, Hui},
title = {Urinary PSA and Serum PSA for Aggressive Prostate Cancer Detection},
journal = {Cancers},
year = {2023},
volume = {15},
number = {3},
pages = {960},
doi = {10.3390/cancers15030960}
}
EUVIMED